SAN DIEGO--(BUSINESS WIRE)--Sep. 7, 2017--
Illumina, Inc. (NASDAQ:ILMN) announced today that the company has filed
a new patent infringement suit against Premaitha Health plc in the High
Court of Justice, Chancery Division, Patents Court in the United
Kingdom. Illumina is seeking all available remedies, including damages
and injunctive relief.
The new suit accuses Premaitha’s IONA® Test of infringing European
Patent (UK) 1 524 321 B2 titled, “Non-invasive Detection of Fetal
Genetic Traits,” which is exclusively licensed to Illumina from
Illumina and its wholly owned subsidiary, Verinata Health, Inc.,
previously filed suits in the UK against Premaitha accusing its Iona
test of infringing European Patent (UK) 0 994 963 B2, European Patent
(UK) 1 981 995 B1, European Patent (UK) 2 183 693 B1, European Patent
(UK) 2 385 143 B1 and European Patent (UK) 2 514 842 B1. Those suits
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. To learn more, visit www.illumina.com
and follow @illumina.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170907005469/en/
Source: Illumina, Inc.
Rebecca Chambers, 858-255-5243